Shares in Prima Biomed (ASX:PRR) soared 60 per cent Tuesday after it announced strong results from the Phase 2 CAN-003 ovarian cancer trial of its CVac vaccine.
The company said that, in the group of second remission patients (n=20), the median standard of care patients was 25.53 months.
"By comparison, for patients treated with CVac a median has still not been reached after 42 months with study completion and closure....This implies at least a 16 months median survival advantage for second remission patients when treated with CVac," it said in a statement.
According to Lucy Turnbull, Chairman of Prima Biomed, "This final clinical data for CVac is most encouraging for cancer patients in second remission. We sincerely thank all patients and medical staff who have participated in the trial over the last five years. Our concerted focus will now be to find a development partner to make CVac widely available to cancer sufferers around the world."
The data is also consistent with previously announced Progression Free Survival (PFS) data that showed a median PFS for CVac of greater than 12.91 months, compared to a median PFS of 4.94 months for the control group.
CEO Marc Voigt said: "The CAN-003 data has shown a consistent and sustained trend for improvement over the years in Progression Free Survival and Overall Survival. The positive effect of cellular therapies and the high quality of life of treated patients support the potential for further developing CVac under license through an industry partner."